A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative, CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT03739814

Title field or adapter rule

{'original_value': 'A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative, CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-11-01T01:03:12.853253+00:00

Published At

2026-10-28T00:00:00+00:00

Record Updated At

2026-10-28

Source Retrieved At

2026-11-01T01:03:12.230707+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative", "Recurrent B Acute Lymphoblastic Leukemia", "Refractory B Acute Lymphoblastic Leukemia"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-28", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT03739814"

protocolSection.identificationModule.officialTitle

"A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative, CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease"

protocolSection.statusModule.overallStatus

"RECRUITING"

protocolSection.designModule.phases

["PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative (protocolSection.conditionsModule.conditions)
• Recurrent B Acute Lymphoblastic Leukemia (protocolSection.conditionsModule.conditions)
• Refractory B Acute Lymphoblastic Leukemia (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['Cohort 1 (inotuzumab ozogamicin, blinatumomab)', 'Cohort 2 (inotuzumab ozogamicin, blinatumomab)', 'Cohort 3 (inotuzumab ozogamicin, blinatumomab, ponatinib))'], 'description': 'Undergo blood sample and cerebrospinal fluid collection', 'name': 'Biospecimen Collection', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Cohort 1 (inotuzumab ozogamicin, blinatumomab)', 'Cohort 2 (inotuzumab ozogamicin, blinatumomab)', 'Cohort 3 (inotuzumab ozogamicin, blinatumomab, ponatinib))'], 'description': 'Given IV', 'name': 'Blinatumomab', 'type': 'BIOLOGICAL'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Cohort 2 (inotuzumab ozogamicin, blinatumomab)', 'Cohort 3 (inotuzumab ozogamicin, blinatumomab, ponatinib))'], 'description': 'Undergo bone marrow aspiration', 'name': 'Bone Marrow Aspiration', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Cohort 1 (inotuzumab ozogamicin, blinatumomab)', 'Cohort 2 (inotuzumab ozogamicin, blinatumomab)', 'Cohort 3 (inotuzumab ozogamicin, blinatumomab, ponatinib))'], 'description': 'Undergo bone marrow biopsy', 'name': 'Bone Marrow Biopsy', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Cohort 1 (inotuzumab ozogamicin, blinatumomab)', 'Cohort 2 (inotuzumab ozogamicin, blinatumomab)', 'Cohort 3 (inotuzumab ozogamicin, blinatumomab, ponatinib))'], 'description': 'Given IV', 'name': 'Inotuzumab Ozogamicin', 'type': 'BIOLOGICAL'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Cohort 1 (inotuzumab ozogamicin, blinatumomab)', 'Cohort 2 (inotuzumab ozogamicin, blinatumomab)', 'Cohort 3 (inotuzumab ozogamicin, blinatumomab, ponatinib))'], 'description': 'Undergo lumbar puncture', 'name': 'Lumbar Puncture', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Cohort 3 (inotuzumab ozogamicin, blinatumomab, ponatinib))'], 'description': 'Given PO', 'name': 'Ponatinib', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• Ponatinib (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.